Skip to main content
. Author manuscript; available in PMC: 2007 Jun 21.
Published in final edited form as: Lancet. 2005 Aug 13;366(9485):549–555. doi: 10.1016/S0140-6736(05)67098-5

Table 1.

Clinical characteristics prior to and during study

Year HIV+ HAART Duration <50 copies/ml CD4/μl (%) VPA μg/ml
total free
Pt. 1 1995 TDF/ABC/D4T/APV/r 38 mo* 1285 (43%) 65.1-83.1 5.8-6.7
Pt. 2 1999 DDI/FTC/Efv >43 mo† 558 (26%) 52.4-89.6 3.0-9.8
Pt. 3 1985 TDF/ABC/3TC/Efv/Nfv >24 mo†* 350 (18%) 56.7-81.0 3.9-6.8
Pt. 4 1995 ZDV/3TC/Nvp >75 mo† 372 (35%) 33.9-74.8 2.2-8.7
†

Viremia was suppressed prior to the first visit of these patients to our clinic.

*

Patient 1: single measurement of 71 copies/ml HIV-1 RNA at week −96. Patient 3 single measurements of 636 copies/ml at week −12, and 98 copies/ml at week −72.

ZDV: zidovudine, 3TC: lamivudine, Nvp: nevirapine, DDI: didanosine, FTC: emtricitibine, Efv: efavirenz, TDF: tenofovir, ABC: abacavir, Nfv: nelfinavir, D4T: stavudine, APV/r: amprenavir with low-dose ritonavir